The Aesthetics Advisor

The era of GLP-1 weight loss drugs is no longer emerging—it’s already dominating modern medicine. In less than five years, medications like Ozempic, Wegovy, Mounjaro, and Zepbound have shifted obesity treatment from marginal success to clinically meaningful, double-digit weight loss backed by large-scale randomized trials . The numbers are not subtle. In pivotal studies, semaglutide (Wegovy) delivered ~15% average weight loss, while tirzepatide (Mounjaro/Zepbound) pushed results beyond 20%—approaching outcomes once only seen with bariatric surgery . At the same time, these drugs are showing cardiovascular risk reduction, improved glycemic control, and potential benefits across fatty liver disease, inflammation, and metabolic syndrome . Yet despite the hype, most comparisons online are superficial—and often misleading. These drugs are not interchangeable . They belong to different pharmacologic classes, target different hormone pathways, and produce meaningfully different outcomes in...